What is Oxygenta Pharmaceutical Ltd (524636) share price return in the past 10 years?

Oxygenta Pharmaceutical Ltd share price has appreciated 16% annually (CAGR) over the past ten years.

What is the share price of Oxygenta Pharmaceutical Ltd (524636)?

Company share prices are keep on changing according to the market conditions. The current trading price of Oxygenta Pharmaceutical Ltd (524636) on 04-Jun-2026 16:59:59 at 16:59 is 50.70.

What is the P/E ratio of Oxygenta Pharmaceutical?

The latest standalone P/E ratio of Oxygenta Pharmaceutical as of 04-Jun-2026 is 0.00.

What is the P/B ratio of Oxygenta Pharmaceutical Ltd (524636)?

The latest standalone P/B ratio of Oxygenta Pharmaceutical Ltd (524636) as of 04-Jun-2026 is -4.40.

What is the 52-week high and low of Oxygenta Pharmaceutical Ltd (524636)?

The 52-week high of Oxygenta Pharmaceutical Ltd (524636) is Rs. 133.50 and the 52-week low is Rs. 45.30.

Oxygenta Pharmaceutical Ltd (524636) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Oxygenta Pharmaceutical Ltd (524636)
Brand: Oxygenta Pharmaceutical

Oxygenta Pharmaceutical Ltd (524636)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524636 NSE: Pharmaceuticals & Drugs | Small Cap | Oxygenta Pharma Share Price

Oxygenta Pharmaceutical Ltd (524636)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524636 NSE: Pharmaceuticals & Drugs | Small Cap | Oxygenta Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹188 Cr.

Current Price

₹50.7

52-Week Low / High

₹45 / 134

TTM EPS

₹-4.8

TTM Sales

₹113 Cr.

Book Value per Share

₹-11.5

P/E Ratio

0.00

Industry PE

46.5

Price to Book (P/B)

-4.40

In line with its 5-year historical median

Price to Sales (P/S)

1.66

Lower than its 5-year historical median

EV/EBITDA

-19.56

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.00%

Underperforms industry median

Return on Capital Employed (ROCE)

-25.62%

Underperforms industry median

Return on Assets (ROA)

-15.24%

Operating Profit Margin

-8.8%

Net Profit Margin

-8.86%

Gross Profit Margin

-9.6%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

175.73%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

56.54%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹-80 Cr.

Equity

₹37 Cr.

Face Value

₹10

All Time Low / High

₹0.10 / 133.50

Oxygenta Pharmaceutical stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Oxygenta Pharmaceutical Ltd a good quality company?

Oxygenta Pharmaceutical Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Oxygenta Pharmaceutical Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Oxygenta Pharmaceutical Ltd vs industry peers?

Oxygenta Pharmaceutical Ltd revenue CAGR is 51.44%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Oxygenta Pharmaceutical Ltd?

Promoters hold 56.54% of the Oxygenta Pharmaceutical Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Oxygenta Pharmaceutical Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 16.5% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0%	0%	0%	0%	0%	0%	3.2%	-50.3%	-41.7%	-25.6%	-
Value Creation Index ⓘ	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
Growth Parameters ⓘ
Sales ⓘ	12.4	8.2	12.9	20.5	13.7	52	60.5	31	39.6	109	113
Sales YoY Gr.	-	-34.4%	57.9%	59.4%	-33.1%	279.2%	16.3%	-48.8%	27.9%	175.7%	-
Adj EPS ⓘ	-5.4	-5.7	-4.4	-3.2	-8.4	2.9	-0	-7.8	-1.1	-2.6	-4.8
YoY Gr.	-	NA	NA	NA	NA	NA	-101.1%	NA	NA	NA	-
BVPS (₹) ⓘ	-21.1	-26.8	-31.3	-34.5	-40.1	-37.3	-24.4	-32.5	-6.2	-6.8	-11.5
Adj Net Profit ⓘ	-5.5	-5.8	-4.5	-3.3	-8.6	2.9	-0	-11.1	-3.5	-9.4	-18
Cash Flow from Ops. ⓘ	0.9	0.5	1.3	-7.8	-2.6	-1.6	-1.7	-1.6	-13.1	2.6	-
Debt/CF from Ops. ⓘ	20.6	37	14.9	-2.9	-10.4	-29.5	-31	-41.6	-4.4	23.9	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	27.3%	51.4%	21.8%	175.7%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	NA	NA	NA	NA
Share Price	16%	47.4%	17.6%	-53.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	29.2	23.7	15.3	9.7	22.5	-7.4	0.1	27.4	10.6	41.7	51.9
Op. Profit Mgn % ⓘ	-33.5	-59.4	-31.1	-10	-57.4	7.4	2.4	-23	-24.4	-8.8	-13.7
Net Profit Mgn % ⓘ	-44.3	-71.2	-35.2	-15.9	-62.5	5.6	-0.1	-35.7	-8.9	-8.6	-15.6
Debt to Equity ⓘ	-0.8	-0.7	-0.6	-0.6	-0.7	-1.3	-1.5	-1.5	-2.8	-2.5	-
Working Cap Days ⓘ	194	290	151	122	216	82	82	217	235	96	105
Cash Conv. Cycle ⓘ	-247	-229	-154	-75	-14	-11	-0	52	26	-2	-131

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	12	8	13	21	14	52	61	31	40	109
Operating Expenses ⓘ +	17	13	17	23	22	48	59	38	49	119
Manufacturing Costs	3	3	3	2	2	6	9	7	7	12
Material Costs	8	6	10	16	16	37	47	24	34	96
Employee Cost	3	3	3	3	2	4	1	6	6	7
Other Costs ⓘ	2	2	1	1	1	2	2	2	2	3
Operating Profit ⓘ	-4	-5	-4	-2	-8	4	1	-7	-10	-10
Operating Profit Margin (%)	-33.5%	-59.4%	-31.1%	-10.0%	-57.4%	7.4%	2.4%	-23.0%	-24.5%	-8.9%
Other Income ⓘ +	0	1	1	0	0	0	0	0	0	1
Exceptional Items ⓘ	0	0	0	0	4	2	1	-1	0	-0
Interest ⓘ	1	1	1	1	1	2	1	1	2	2
Depreciation ⓘ	1	1	1	1	1	1	2	2	3	1
Profit Before Tax ⓘ	-6	-6	-4	-3	-6	3	-0	-11	-14	-12
Tax ⓘ	-0	0	0	-0	-0	0	0	0	-10	-2
Profit After Tax	-5	-6	-5	-3	-6	3	-1	-12	-3	-10
PAT Margin (%)	-44.3%	-71.2%	-35.2%	-15.9%	-42.2%	5.6%	-1.0%	-37.3%	-8.8%	-8.9%
Adjusted EPS (₹)	-5.4	-5.7	-4.4	-3.2	-5.7	2.9	-0.4	-8.2	-1.0	-2.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Oxygenta Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	-22	-27	-32	-35	-41	-38	-35	-46	-21	-25
Share Capital ⓘ	10	10	10	10	10	10	14	14	33	37
Reserves ⓘ	-32	-38	-42	-45	-51	-48	-49	-60	-54	-62
Debt +	17	18	18	21	26	48	52	67	56	61
Long Term Debt	17	18	18	21	25	45	51	62	49	22
Short Term Debt	0	0	0	0	0	3	1	5	7	40
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	15	9	11	9	8	14	6	24	23	30
Others Liabilities ⓘ	10	19	20	26	26	10	7	9	-4	6
Total Liabilities ⓘ	20	19	17	21	19	34	31	54	54	73
Fixed Assets
Net Fixed Assets ⓘ +	13	12	12	12	11	16	20	28	29	40
Gross Block	23	23	24	25	25	31	36	46	51	61
Accumulated Depreciation	10	11	12	13	14	15	16	19	21	22
CWIP ⓘ	0	0	0	0	0	1	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	1	2	2	5	4	12	7	12	14	21
Trade Receivables	1	1	0	1	0	2	2	10	7	5
Cash Equivalents	0	0	0	0	0	0	0	0	0	0
Others Assets ⓘ	4	3	3	3	2	3	2	4	4	7
Total Assets ⓘ	20	19	17	21	19	34	31	54	54	73

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	1	1	1	-8	-3	-2	-2	-2	-13	3
PBT ⓘ	-6	-6	-4	-3	-6	3	-0	-11	-14	-12
Adjustment ⓘ	1	1	2	2	2	3	3	4	4	2
Changes in Working Capital ⓘ	5	5	4	-6	1	-8	-4	6	-3	12
Tax Paid ⓘ	0	-0	-0	0	0	-0	-0	0	0	-0
Cash Flow From Investing Activity ⓘ +	-2	-1	-0	-1	-0	-7	-5	-10	-4	-11
Capex	-2	-1	-0	-1	-1	-7	-5	0	-4	-11
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	-10	0	0
Cash Flow From Financing Activity ⓘ +	1	0	-1	8	3	9	6	11	17	9
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	4	0	29	5
Net Proceeds from Borrowing ⓘ	2	1	0	9	4	10	3	13	-11	-27
Interest Paid ⓘ	-1	-1	-1	-1	-1	-2	-1	-1	-2	-2
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0	0	0	-0	0	-0	0	0	1	32
Net Cash Flow ⓘ	-0	0	-0	0	0	0	-0	-0	-0	0

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROCE (%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover Ratio	0.66	0.42	0.71	1.08	0.69	1.98	1.86	0.73	0.73	1.72
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	-0.67	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	31.20	52.50	19	8.80	12.50	7.10	9.60	69.10	80.70	20.80
Inventory Days	21.40	62.90	48.80	61.30	127.50	57.40	58.50	111.80	117	57.20
Payable Days	583.70	790.10	367.70	223.70	199.80	109.10	78.30	229.90	254	99.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Oxygenta Pharmaceutical Ltd FAQs

The current trading price of Oxygenta Pharma on 04-Jun-2026 16:59 is ₹50.70.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Oxygenta Pharma stood at ₹187.5 Cr

The latest P/E ratio of Oxygenta Pharma as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Oxygenta Pharma as of 03-Jun-2026 is -4.40.

The 52-week high of Oxygenta Pharma is ₹133.5 and the 52-week low is ₹45.30.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Oxygenta Pharma is ₹113 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Oxygenta Pharmaceutical Ltd is a below average quality company.

The key valuation ratios of Oxygenta Pharmaceutical Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Oxygenta Pharmaceutical Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Oxygenta Pharmaceutical Ltd

SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.

A wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs are manufactured. The product range also includes omeprazole, rabeprazole sodium, lansoprazole, esomeprazole magnesium trihydrate, non-pariel seeds, pantoprazole pellets, diclofenac sodium pellets, gabapentior, mooxafloxacin, ramipril, atorvastatin, and voriconazole.

Designed and built as per US FDA standards for production of bulk drugs and custom synthesis of intermediates, the plant located in the Medak district of Andhra Pradesh has an installed capacity 320 TPA. Major export destinations include Europe, USA, South America, and Asia Pacific Region. It reaches the America markets through its subsidiary based in Maryland, USA.

The registered office is at Survey No 252/1, Aroor Village, Sadasivapet Mandal, Medak, Andhra Pradesh.

Oxygenta Pharmaceutical Ltd (524636)

Oxygenta Pharmaceutical Ltd (524636)

Oxygenta Pharmaceutical stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Oxygenta Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Oxygenta Pharmaceutical Ltd FAQs

About Oxygenta Pharmaceutical Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Oxygenta Pharmaceutical Ltd (524636)

Oxygenta Pharmaceutical Ltd (524636)

Oxygenta Pharmaceutical stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Oxygenta Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Oxygenta Pharmaceutical Ltd FAQs

What is the share price of Oxygenta Pharma?

What is the market cap of Oxygenta Pharma?

What is the P/E ratio of Oxygenta Pharma?

What is the P/B ratio of Oxygenta Pharma?

What is the 52-week high and low of Oxygenta Pharma?

What is the TTM revenue of Oxygenta Pharma?

Is Oxygenta Pharmaceutical Ltd a good quality company?

Is Oxygenta Pharmaceutical Ltd undervalued or overvalued?

Is Oxygenta Pharmaceutical Ltd a good buy now?

About Oxygenta Pharmaceutical Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.